Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Home About Us My Account Personal Library Customer Service    
Welcome Guest
(login/register)
US: 800.298.5699
Int'l: +1.240.747.3093
Quick Search
Advanced Search >
Research Assistance
Send us a request >
Latest Research by Email
Receive email alerts of new market research reports in your industry.
Sign Up Today >
Home > Back to Category > Report Information Email a colleague | Printer format

Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the United Kingdom

JustPharmaReports.com
April 1, 2009
107 Pages - Pub ID: JPM2215357
 
Questions about this report >
Order by fax >
XE.com
Abstract

Table of
Contents
Search Inside
this Report
Related Reports


Countries covered: United Kingdom

In an otherwise volatile pharmaceutical world, 2009 has seen two notable and durable anniversaries, the implementation of the tenth re-negotiated Pharmaceutical Price Regulation Scheme in January and the tenth birthday of the National Institute for Health and Clinical Excellence in April. PPRS and NICE, are among abbreviations most widely recognised, but their structures, functions and ways of working are often less than fully understood.

‘Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the UK’ delivers what it says in the title. It provides in one place fully-researched, up-to-date information and interpretation on all the market access barriers facing pharmaceutical companies in the four countries that make up the United Kingdom.

The UK has a much bigger global impact in pricing and health technology assessment terms than its market size would suggest. It is a key lead-off one for launches. While accounting for less than 4% of world demand for prescription medicines, other countries that set prices with reference to those in the UK together account for 25% of that demand. Like them or hate them, the PPRS and NICE are original, well-established and influential models that governments and industry bodies elsewhere look to.

The report addresses:
  • The UK’s complex decision-making processes for funding of medicines.
  • The procedures and outcomes of the three HTA bodies, NICE, SMC and AWMSG.
  • How and why the 2009 PPRS evolved in the way it did, and what this means for companies selling medicines to the NHS.
  • The pros and cons of joining the voluntary or alternative statutory scheme.
  • All the changes in the new PPRS and the prospects for the more novel but contentious parts, including flexible pricing, patient access schemes and generic substitution.
  • What jargon including ‘end-of-life treatment’, ‘horizon scanning’, ‘NICE blight’,‘OFT wedge’ ‘outturn’, ‘QALY’, ‘safety value’ and ‘top-up’ actually mean.
  • Other cost containment measures impacting on prescribers, patients and the distribution chain.

Related Reports:
Snapshots US Pharmaceuticals 2009
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Pharmaceuticals Industry Report
Pharmaceutical Industry in Mexico
Emerging Markets Series: Indonesia and Philippines
H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
Antipsychotics Market Forecast
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
Prescription Drug Wholesaling in the US - Industry Risk Rating Report
Antidepressants Market Forecast

Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 2